Overview
In April 2008, GSK and Regulus Therapeutics announced the first ever microRNA-focused strategic alliance to discover, develop and commercialize novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory disease. Valued at nearly $600 million, the alliance provides GSK with an option to exclusively license drug candidates directed at four different microRNA targets with relevance in inflammatory disease. Regulus is responsible for the discovery and development of the microRNA antagonists through completion of clinical proof of concept. GSK has the option to license each drug developed by Regulus for the relevant microRNA target for further development and commercialization on a worldwide basis.
